Hemab (COAG) Q3 2026 Earnings Call Transcript
Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

